Jeffrey M. Jacobstein
Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
Articles
AIA Patent Claims Canceled by Pre-AIA Application Interference
USA - February 11 2022 In yet another round of the ever-expanding disputes surrounding CRISPR technology, the Patent Trial and Appeal Board (PTAB) recently denied priority…
Life Sciences Podcast Series - Patent Applications Based on Clinical Trials
USA - February 26 2021 The Life Sciences industry can be particularly challenging for companies to navigate, often requiring careful navigation through rigorous testing and…
Update to the Purple Book in Recent COVID-19 Stimulus Bill and Implications for BPCIA Litigation
USA - December 23 2020 On December 21, 2020, Congress passed a second COVID-19 stimulus bill. Buried among the 5500 pages of the 900 billion dollar relief package was…
Considerations in Demonstrating Interchangeability with a Reference Biologic Product
USA - August 12 2019 N May 9, 2019, FDA issued final guidance, Considerations in Demonstrating Interchangeability with a Reference Product (1). This article provides a…
Federal Circuit Casts Doubt on Antibodies Claimed by Epitope
USA - October 12 2017 In Amgen Inc. v. Sanofi, No. 2017-1480, the Federal Circuit reversed and remanded for a new trial because the district court (1) incorrectly excluded…
